Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers

The cell adhesion protein CD56 has been identified as a potential therapeutic target in several solid tumors and hematological malignancies. Recently, we developed a CD56-directed antibody-drug conjugate (ADC), called Adcitmer and demonstrated its antitumor properties in preclinical models of the ra...

Descrizione completa

Dettagli Bibliografici

Autori principali:	David Schrama, Antoine Touze, Thibault Kervarrec, Mahtab Samimi, Valérie Gouilleux-Gruart, Aurelie Drouin, Laurine Durand, Clara Esnault, Pauline Gaboriaud, Valérie Leblond, Shawk Karim, Morgane Fouché, Christine Dhommée, Christine B Baltus, Fanny Boursin, Nicolas Aubrey, Roland Houben, Serge Guyétant, Audrey Desgranges, Marie Claude Viaud-Massuard
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMJ Publishing Group 2025-03-01
Serie:	Journal for ImmunoTherapy of Cancer
Accesso online:	https://jitc.bmj.com/content/13/3/e010897.full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!